Stem definition | Drug id | CAS RN |
---|---|---|
4523 | 130-95-0 |
Dose | Unit | Route |
---|---|---|
1.50 | g | O |
1.50 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 111.10 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 12 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 71.07 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 1.80 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.30 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 11 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 12, 2005 | FDA | MUTUAL PHARM CO INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug abuse | 208.16 | 13.42 | 148 | 12379 | 59698 | 50532899 |
Labile blood pressure | 152.82 | 13.42 | 42 | 12485 | 1618 | 50590979 |
Somatic symptom disorder | 94.50 | 13.42 | 30 | 12497 | 1914 | 50590683 |
Sacroiliitis | 89.83 | 13.42 | 31 | 12496 | 2566 | 50590031 |
Lipase increased | 82.73 | 13.42 | 41 | 12486 | 8500 | 50584097 |
Hepatic ischaemia | 78.05 | 13.42 | 20 | 12507 | 585 | 50592012 |
Haematemesis | 74.90 | 13.42 | 59 | 12468 | 27666 | 50564931 |
Hepatorenal syndrome | 72.90 | 13.42 | 24 | 12503 | 1719 | 50590878 |
Hepatic failure | 59.17 | 13.42 | 55 | 12472 | 32228 | 50560369 |
Muscle relaxant therapy | 55.47 | 13.42 | 12 | 12515 | 164 | 50592433 |
Coronary artery disease | 53.24 | 13.42 | 50 | 12477 | 29676 | 50562921 |
Renal failure | 48.19 | 13.42 | 91 | 12436 | 106542 | 50486055 |
Drug ineffective | 46.24 | 13.42 | 83 | 12444 | 819250 | 49773347 |
Coagulopathy | 45.92 | 13.42 | 37 | 12490 | 17907 | 50574690 |
Hyponatraemia | 43.38 | 13.42 | 82 | 12445 | 96057 | 50496540 |
Thrombotic microangiopathy | 43.19 | 13.42 | 27 | 12500 | 8764 | 50583833 |
Drug hypersensitivity | 41.14 | 13.42 | 146 | 12381 | 250864 | 50341733 |
Electrocardiogram QT prolonged | 40.86 | 13.42 | 57 | 12470 | 51829 | 50540768 |
Mood altered | 40.69 | 13.42 | 30 | 12497 | 12743 | 50579854 |
Hypovolaemia | 38.94 | 13.42 | 26 | 12501 | 9439 | 50583158 |
Duodenal ulcer | 38.92 | 13.42 | 23 | 12504 | 6752 | 50585845 |
Toxicity to various agents | 38.66 | 13.42 | 128 | 12399 | 212371 | 50380226 |
Fear of eating | 37.86 | 13.42 | 10 | 12517 | 330 | 50592267 |
Gastrointestinal haemorrhage | 33.63 | 13.42 | 63 | 12464 | 73258 | 50519339 |
Off label use | 33.53 | 13.42 | 41 | 12486 | 474385 | 50118212 |
Post procedural haemorrhage | 32.41 | 13.42 | 21 | 12506 | 7249 | 50585348 |
Product dose omission issue | 31.85 | 13.42 | 4 | 12523 | 183834 | 50408763 |
Coronary artery bypass | 31.45 | 13.42 | 14 | 12513 | 2279 | 50590318 |
Drug intolerance | 31.01 | 13.42 | 8 | 12519 | 219096 | 50373501 |
Cognitive disorder | 29.68 | 13.42 | 45 | 12482 | 44078 | 50548519 |
Retinal toxicity | 29.14 | 13.42 | 11 | 12516 | 1177 | 50591420 |
Infusion related reaction | 28.63 | 13.42 | 4 | 12523 | 169553 | 50423044 |
Pancreatitis | 28.01 | 13.42 | 43 | 12484 | 42571 | 50550026 |
Cinchonism | 26.98 | 13.42 | 4 | 12523 | 3 | 50592594 |
Rhabdomyolysis | 26.53 | 13.42 | 40 | 12487 | 38987 | 50553610 |
Swollen tongue | 26.43 | 13.42 | 34 | 12493 | 28596 | 50564001 |
Fatigue | 26.20 | 13.42 | 89 | 12438 | 707512 | 49885085 |
Blood sodium decreased | 25.90 | 13.42 | 29 | 12498 | 21118 | 50571479 |
Rheumatoid arthritis | 25.75 | 13.42 | 9 | 12518 | 202541 | 50390056 |
Purpura senile | 25.03 | 13.42 | 8 | 12519 | 521 | 50592076 |
Vestibular disorder | 24.92 | 13.42 | 10 | 12517 | 1259 | 50591338 |
Tarsal tunnel syndrome | 24.89 | 13.42 | 8 | 12519 | 531 | 50592066 |
Vascular injury | 24.86 | 13.42 | 9 | 12518 | 856 | 50591741 |
Myocardial ischaemia | 23.65 | 13.42 | 21 | 12506 | 11592 | 50581005 |
Oral cavity fistula | 23.50 | 13.42 | 8 | 12519 | 635 | 50591962 |
Salivary gland enlargement | 23.47 | 13.42 | 7 | 12520 | 362 | 50592235 |
Optic ischaemic neuropathy | 23.44 | 13.42 | 9 | 12518 | 1008 | 50591589 |
Product use issue | 22.04 | 13.42 | 5 | 12522 | 149470 | 50443127 |
Hiccups | 21.89 | 13.42 | 10 | 12517 | 1729 | 50590868 |
Exostosis of jaw | 21.86 | 13.42 | 9 | 12518 | 1210 | 50591387 |
Cerebral artery occlusion | 21.23 | 13.42 | 8 | 12519 | 852 | 50591745 |
Muscle necrosis | 21.21 | 13.42 | 7 | 12520 | 505 | 50592092 |
Eczema asteatotic | 21.16 | 13.42 | 6 | 12521 | 259 | 50592338 |
Abdominal discomfort | 20.99 | 13.42 | 16 | 12511 | 231625 | 50360972 |
Synovitis | 20.72 | 13.42 | 3 | 12524 | 123862 | 50468735 |
Acute kidney injury | 20.62 | 13.42 | 111 | 12416 | 227947 | 50364650 |
Exposed bone in jaw | 20.11 | 13.42 | 11 | 12516 | 2789 | 50589808 |
Resorption bone increased | 19.97 | 13.42 | 8 | 12519 | 1003 | 50591594 |
Fibromyalgia | 19.81 | 13.42 | 38 | 12489 | 44940 | 50547657 |
Left ventricular dysfunction | 19.43 | 13.42 | 18 | 12509 | 10488 | 50582109 |
Haemolytic uraemic syndrome | 19.15 | 13.42 | 10 | 12517 | 2309 | 50590288 |
Abdominal rigidity | 18.97 | 13.42 | 9 | 12518 | 1695 | 50590902 |
Ulcer | 18.66 | 13.42 | 24 | 12503 | 20176 | 50572421 |
Adrenal mass | 18.23 | 13.42 | 7 | 12520 | 785 | 50591812 |
Hepatocellular injury | 18.21 | 13.42 | 27 | 12500 | 25920 | 50566677 |
Nail infection | 17.68 | 13.42 | 9 | 12518 | 1972 | 50590625 |
Hepatic enzyme increased | 17.63 | 13.42 | 6 | 12521 | 137374 | 50455223 |
Fall | 17.46 | 13.42 | 142 | 12385 | 334790 | 50257807 |
Discomfort | 17.28 | 13.42 | 3 | 12524 | 108377 | 50484220 |
Pain | 16.83 | 13.42 | 80 | 12447 | 578823 | 50013774 |
Myocardial infarction | 16.47 | 13.42 | 54 | 12473 | 88973 | 50503624 |
Cerebrovascular accident | 16.26 | 13.42 | 56 | 12471 | 94624 | 50497973 |
Injection site pain | 15.80 | 13.42 | 4 | 12523 | 111020 | 50481577 |
Therapeutic product effect decreased | 15.71 | 13.42 | 7 | 12520 | 136043 | 50456554 |
Hand deformity | 15.49 | 13.42 | 3 | 12524 | 100196 | 50492401 |
Agitated depression | 15.45 | 13.42 | 4 | 12523 | 122 | 50592475 |
Rectal haemorrhage | 15.08 | 13.42 | 31 | 12496 | 38527 | 50554070 |
Gastritis | 14.69 | 13.42 | 28 | 12499 | 32955 | 50559642 |
Hyperkalaemia | 14.67 | 13.42 | 35 | 12492 | 48054 | 50544543 |
Sequestrectomy | 14.55 | 13.42 | 6 | 12521 | 810 | 50591787 |
Sedation complication | 14.28 | 13.42 | 14 | 12513 | 8752 | 50583845 |
Sinusitis | 13.94 | 13.42 | 13 | 12514 | 170545 | 50422052 |
Vaginal discharge | 13.82 | 13.42 | 11 | 12516 | 5229 | 50587368 |
Disseminated intravascular coagulation | 13.74 | 13.42 | 19 | 12508 | 17116 | 50575481 |
Multiple organ dysfunction syndrome | 13.63 | 13.42 | 35 | 12492 | 50302 | 50542295 |
Nephrogenic systemic fibrosis | 13.42 | 13.42 | 10 | 12517 | 4312 | 50588285 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug abuse | 1059.02 | 16.22 | 469 | 6709 | 79414 | 29487935 |
Toxicity to various agents | 254.88 | 16.22 | 258 | 6920 | 173403 | 29393946 |
Poisoning | 88.98 | 16.22 | 45 | 7133 | 9948 | 29557401 |
Exposure via ingestion | 58.44 | 16.22 | 21 | 7157 | 1997 | 29565352 |
Intentional product misuse | 54.96 | 16.22 | 54 | 7124 | 34607 | 29532742 |
Compartment syndrome | 47.42 | 16.22 | 19 | 7159 | 2433 | 29564916 |
Electrocardiogram U wave present | 42.09 | 16.22 | 7 | 7171 | 19 | 29567330 |
Atrioventricular block | 36.12 | 16.22 | 22 | 7156 | 6960 | 29560389 |
Cinchonism | 33.68 | 16.22 | 5 | 7173 | 4 | 29567345 |
Toxic neuropathy | 31.33 | 16.22 | 9 | 7169 | 416 | 29566933 |
Mouth swelling | 29.74 | 16.22 | 12 | 7166 | 1564 | 29565785 |
Hypomagnesaemia | 29.14 | 16.22 | 28 | 7150 | 17440 | 29549909 |
Urine sodium decreased | 28.82 | 16.22 | 7 | 7171 | 167 | 29567182 |
Agitated depression | 26.76 | 16.22 | 7 | 7171 | 227 | 29567122 |
Lower respiratory tract infection | 25.82 | 16.22 | 32 | 7146 | 26470 | 29540879 |
Nephrogenic systemic fibrosis | 24.53 | 16.22 | 14 | 7164 | 3928 | 29563421 |
Drug ineffective | 22.94 | 16.22 | 33 | 7145 | 363137 | 29204212 |
Cerebral malaria | 21.97 | 16.22 | 3 | 7175 | 0 | 29567349 |
Unresponsive to stimuli | 20.81 | 16.22 | 28 | 7150 | 25098 | 29542251 |
Infected skin ulcer | 20.73 | 16.22 | 9 | 7169 | 1408 | 29565941 |
Confusional state | 20.60 | 16.22 | 73 | 7105 | 127804 | 29439545 |
Alveolar proteinosis | 20.05 | 16.22 | 6 | 7172 | 320 | 29567029 |
Increased bronchial secretion | 19.78 | 16.22 | 9 | 7169 | 1572 | 29565777 |
Body mass index decreased | 19.39 | 16.22 | 5 | 7173 | 153 | 29567196 |
Cutaneous extramedullary haemopoiesis | 18.68 | 16.22 | 3 | 7175 | 6 | 29567343 |
Hypocalcaemia | 18.61 | 16.22 | 24 | 7154 | 20641 | 29546708 |
Lethargy | 18.60 | 16.22 | 33 | 7145 | 37547 | 29529802 |
Blood sodium decreased | 17.99 | 16.22 | 20 | 7158 | 14747 | 29552602 |
Skin induration | 17.54 | 16.22 | 9 | 7169 | 2045 | 29565304 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug abuse | 1178.78 | 13.28 | 620 | 17270 | 131754 | 64349088 |
Toxicity to various agents | 229.89 | 13.28 | 382 | 17508 | 363131 | 64117711 |
Thrombotic microangiopathy | 170.27 | 13.28 | 86 | 17804 | 16569 | 64464273 |
Labile blood pressure | 134.43 | 13.28 | 41 | 17849 | 2039 | 64478803 |
Somatic symptom disorder | 92.30 | 13.28 | 30 | 17860 | 1838 | 64479004 |
Sacroiliitis | 81.89 | 13.28 | 31 | 17859 | 2981 | 64477861 |
Poisoning | 76.82 | 13.28 | 57 | 17833 | 21822 | 64459020 |
Hepatic ischaemia | 65.42 | 13.28 | 20 | 17870 | 1002 | 64479840 |
Drug ineffective | 65.00 | 13.28 | 83 | 17807 | 840164 | 63640678 |
Exposure via ingestion | 61.12 | 13.28 | 29 | 17861 | 4873 | 64475969 |
Cinchonism | 59.54 | 13.28 | 9 | 17881 | 7 | 64480835 |
Haematemesis | 57.44 | 13.28 | 68 | 17822 | 46931 | 64433911 |
Hepatorenal syndrome | 55.57 | 13.28 | 25 | 17865 | 3721 | 64477121 |
Muscle relaxant therapy | 54.11 | 13.28 | 12 | 17878 | 164 | 64480678 |
Hyponatraemia | 53.03 | 13.28 | 123 | 17767 | 148216 | 64332626 |
Microangiopathic haemolytic anaemia | 51.94 | 13.28 | 18 | 17872 | 1344 | 64479498 |
Intentional product misuse | 45.40 | 13.28 | 76 | 17814 | 72219 | 64408623 |
Off label use | 45.30 | 13.28 | 66 | 17824 | 632740 | 63848102 |
Acute kidney injury | 44.30 | 13.28 | 243 | 17647 | 448997 | 64031845 |
Agitated depression | 42.85 | 13.28 | 11 | 17879 | 288 | 64480554 |
Product dose omission issue | 42.42 | 13.28 | 3 | 17887 | 194744 | 64286098 |
Atrioventricular block | 39.28 | 13.28 | 30 | 17860 | 11985 | 64468857 |
Compartment syndrome | 35.08 | 13.28 | 19 | 17871 | 4213 | 64476629 |
Blood sodium decreased | 34.93 | 13.28 | 42 | 17848 | 29440 | 64451402 |
Fear of eating | 34.76 | 13.28 | 10 | 17880 | 405 | 64480437 |
Mood altered | 33.75 | 13.28 | 31 | 17859 | 15948 | 64464894 |
Retinal toxicity | 33.68 | 13.28 | 13 | 17877 | 1317 | 64479525 |
Rhabdomyolysis | 32.68 | 13.28 | 76 | 17814 | 91650 | 64389192 |
Coagulopathy | 32.27 | 13.28 | 42 | 17848 | 31878 | 64448964 |
Coronary artery disease | 30.81 | 13.28 | 58 | 17832 | 60375 | 64420467 |
Swollen tongue | 30.78 | 13.28 | 43 | 17847 | 34911 | 64445931 |
Hypovolaemia | 30.70 | 13.28 | 29 | 17861 | 15457 | 64465385 |
Electrocardiogram U wave present | 30.36 | 13.28 | 7 | 17883 | 115 | 64480727 |
Hepatic failure | 29.28 | 13.28 | 54 | 17836 | 55340 | 64425502 |
Nephrogenic systemic fibrosis | 29.25 | 13.28 | 19 | 17871 | 5873 | 64474969 |
Duodenal ulcer | 28.55 | 13.28 | 27 | 17863 | 14408 | 64466434 |
Renal failure | 27.95 | 13.28 | 112 | 17778 | 181576 | 64299266 |
Rheumatoid arthritis | 27.45 | 13.28 | 6 | 17884 | 164288 | 64316554 |
Exposed bone in jaw | 27.09 | 13.28 | 15 | 17875 | 3472 | 64477370 |
Electrocardiogram QT prolonged | 26.32 | 13.28 | 64 | 17826 | 79384 | 64401458 |
Fatigue | 26.16 | 13.28 | 113 | 17777 | 748617 | 63732225 |
Post procedural haemorrhage | 26.03 | 13.28 | 24 | 17866 | 12407 | 64468435 |
Toxic neuropathy | 24.59 | 13.28 | 9 | 17881 | 787 | 64480055 |
Cognitive disorder | 24.59 | 13.28 | 50 | 17840 | 55037 | 64425805 |
Tarsal tunnel syndrome | 24.50 | 13.28 | 8 | 17882 | 497 | 64480345 |
Purpura senile | 24.41 | 13.28 | 8 | 17882 | 503 | 64480339 |
Hypocalcaemia | 23.72 | 13.28 | 42 | 17848 | 41711 | 64439131 |
Fall | 23.26 | 13.28 | 196 | 17694 | 416630 | 64064212 |
Hypomagnesaemia | 23.06 | 13.28 | 39 | 17851 | 37337 | 64443505 |
Lethargy | 22.49 | 13.28 | 57 | 17833 | 72537 | 64408305 |
Salivary gland enlargement | 22.42 | 13.28 | 7 | 17883 | 376 | 64480466 |
Vascular injury | 22.18 | 13.28 | 9 | 17881 | 1040 | 64479802 |
Infusion related reaction | 22.05 | 13.28 | 9 | 17881 | 164458 | 64316384 |
Cerebral malaria | 21.57 | 13.28 | 3 | 17887 | 0 | 64480842 |
Cardiovascular disorder | 21.10 | 13.28 | 24 | 17866 | 15857 | 64464985 |
Exostosis of jaw | 21.05 | 13.28 | 9 | 17881 | 1185 | 64479657 |
Confusional state | 20.97 | 13.28 | 134 | 17756 | 261010 | 64219832 |
Gastrointestinal haemorrhage | 20.68 | 13.28 | 82 | 17808 | 132230 | 64348612 |
Contraindicated product administered | 20.03 | 13.28 | 3 | 17887 | 107826 | 64373016 |
Ulcer | 19.82 | 13.28 | 28 | 17862 | 22962 | 64457880 |
Drug intolerance | 19.78 | 13.28 | 14 | 17876 | 187978 | 64292864 |
Myocardial ischaemia | 19.57 | 13.28 | 28 | 17862 | 23223 | 64457619 |
Unresponsive to stimuli | 19.32 | 13.28 | 43 | 17847 | 50350 | 64430492 |
Hepatic enzyme increased | 19.31 | 13.28 | 6 | 17884 | 129937 | 64350905 |
Product use issue | 19.23 | 13.28 | 9 | 17881 | 151706 | 64329136 |
Fibromyalgia | 19.09 | 13.28 | 35 | 17855 | 35696 | 64445146 |
Bradycardia | 19.07 | 13.28 | 74 | 17816 | 118145 | 64362697 |
Liver function test abnormal | 18.77 | 13.28 | 47 | 17843 | 59354 | 64421488 |
Injection site pain | 18.74 | 13.28 | 4 | 17886 | 111404 | 64369438 |
Oral cavity fistula | 18.53 | 13.28 | 7 | 17883 | 669 | 64480173 |
Lower respiratory tract infection | 18.45 | 13.28 | 63 | 17827 | 94551 | 64386291 |
Cerebrovascular accident | 18.18 | 13.28 | 81 | 17809 | 137502 | 64343340 |
Treatment failure | 18.08 | 13.28 | 5 | 17885 | 116811 | 64364031 |
Resorption bone increased | 17.98 | 13.28 | 8 | 17882 | 1160 | 64479682 |
Synovitis | 17.86 | 13.28 | 3 | 17887 | 99087 | 64381755 |
Melaena | 17.59 | 13.28 | 43 | 17847 | 53505 | 64427337 |
Plasmodium falciparum infection | 17.45 | 13.28 | 4 | 17886 | 64 | 64480778 |
Blindness transient | 17.36 | 13.28 | 12 | 17878 | 4110 | 64476732 |
Nail infection | 17.31 | 13.28 | 9 | 17881 | 1838 | 64479004 |
Skin induration | 17.22 | 13.28 | 12 | 17878 | 4163 | 64476679 |
Eczema asteatotic | 17.08 | 13.28 | 6 | 17884 | 466 | 64480376 |
Optic ischaemic neuropathy | 17.07 | 13.28 | 10 | 17880 | 2575 | 64478267 |
Cardiac arrest | 16.93 | 13.28 | 86 | 17804 | 153978 | 64326864 |
Blindness | 16.35 | 13.28 | 25 | 17865 | 21994 | 64458848 |
Product use in unapproved indication | 16.27 | 13.28 | 15 | 17875 | 176603 | 64304239 |
Alveolar proteinosis | 15.88 | 13.28 | 6 | 17884 | 574 | 64480268 |
Coronary artery bypass | 15.75 | 13.28 | 13 | 17877 | 5802 | 64475040 |
Cerebral artery occlusion | 15.53 | 13.28 | 8 | 17882 | 1603 | 64479239 |
Lip swelling | 15.49 | 13.28 | 30 | 17860 | 31877 | 64448965 |
Vestibular disorder | 15.49 | 13.28 | 9 | 17881 | 2284 | 64478558 |
Vaginal discharge | 15.35 | 13.28 | 11 | 17879 | 3986 | 64476856 |
Mouth swelling | 15.06 | 13.28 | 12 | 17878 | 5095 | 64475747 |
Respiratory arrest | 14.77 | 13.28 | 40 | 17850 | 52945 | 64427897 |
Muscle necrosis | 14.53 | 13.28 | 7 | 17883 | 1216 | 64479626 |
Therapeutic product effect decreased | 14.38 | 13.28 | 7 | 17883 | 115344 | 64365498 |
Abdominal rigidity | 14.36 | 13.28 | 9 | 17881 | 2618 | 64478224 |
Depressed level of consciousness | 13.97 | 13.28 | 52 | 17838 | 81384 | 64399458 |
International normalised ratio increased | 13.96 | 13.28 | 51 | 17839 | 79116 | 64401726 |
Myocardial infarction | 13.86 | 13.28 | 86 | 17804 | 165735 | 64315107 |
Increased bronchial secretion | 13.71 | 13.28 | 9 | 17881 | 2833 | 64478009 |
Rectal haemorrhage | 13.70 | 13.28 | 43 | 17847 | 61774 | 64419068 |
Sequestrectomy | 13.66 | 13.28 | 6 | 17884 | 843 | 64479999 |
Left ventricular dysfunction | 13.66 | 13.28 | 20 | 17870 | 16934 | 64463908 |
None
Source | Code | Description |
---|---|---|
ATC | M09AA72 | MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Quinine and derivatives |
ATC | P01BC01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Methanolquinolines |
FDA EPC | N0000175482 | Antimalarial |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000962 | Antimalarials |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D000981 | Antiprotozoal Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D009125 | Muscle Relaxants, Central |
MeSH PA | D009465 | Neuromuscular Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:38068 | antimalarials |
CHEBI has role | CHEBI:51371 | muscle relaxants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Falciparum malaria | indication | 62676009 | DOID:14067 |
Chloroquine Resistant Plasmodium Falciparum Malaria | indication | ||
Babesiosis | off-label use | 21061004 | DOID:9643 |
Atrial flutter | contraindication | 5370000 | |
Torsades de pointes | contraindication | 31722008 | |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Atrial fibrillation | contraindication | 49436004 | DOID:0060224 |
Neuromuscular block, function | contraindication | 55394004 | |
Black water fever | contraindication | 56625005 | DOID:14068 |
Acute nephropathy | contraindication | 58574008 | |
Optic neuritis | contraindication | 66760008 | DOID:1210 |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Hemolytic uremic syndrome | contraindication | 111407006 | DOID:12554 |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Prolonged QT interval | contraindication | 111975006 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Congenital long QT syndrome | contraindication | 442917000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.44 | acidic |
pKa2 | 8.02 | Basic |
pKa3 | 4.1 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Potassium voltage-gated channel subfamily H member 2 | Ion channel | WOMBAT-PK | |||||||
Multidrug resistance protein 1 | Transporter | Ki | 4.92 | CHEMBL | |||||
Hemoglobin subunit alpha | Secreted | WOMBAT-PK | |||||||
Potassium voltage-gated channel subfamily B member 2 | Ion channel | BLOCKER | IC50 | 4.90 | IUPHAR | ||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.29 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.36 | CHEMBL | |||||
Equilibrative nucleoside transporter 4 | Transporter | INHIBITOR | Ki | 4.57 | IUPHAR |
ID | Source |
---|---|
D08460 | KEGG_DRUG |
6183-68-2 | SECONDARY_CAS_RN |
6119-70-6 | SECONDARY_CAS_RN |
4018620 | VANDF |
4019926 | VANDF |
CHEBI:15854 | CHEBI |
QI9 | PDB_CHEM_ID |
CHEMBL170 | ChEMBL_ID |
CHEMBL2359966 | ChEMBL_ID |
2510 | IUPHAR_LIGAND_ID |
DB00468 | DRUGBANK_ID |
A7V27PHC7A | UNII |
3034034 | PUBCHEM_CID |
647128 | RXNORM |
5023 | MMSL |
5405 | MMSL |
84102 | MMSL |
d00366 | MMSL |
002934 | NDDF |
002935 | NDDF |
373497008 | SNOMEDCT_US |
47065008 | SNOMEDCT_US |
47857006 | SNOMEDCT_US |
D011803 | MESH_DESCRIPTOR_UI |
C0034417 | UMLSCUI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Quinine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3002 | CAPSULE | 324 mg | ORAL | ANDA | 31 sections |
Qualaquin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13310-153 | CAPSULE | 324 mg | ORAL | NDA | 32 sections |
QUALAQUIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-595 | CAPSULE | 324 mg | ORAL | NDA | 32 sections |
Qualaquin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49708-153 | CAPSULE | 324 mg | ORAL | NDA | 32 sections |
QUININE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-238 | CAPSULE | 324 mg | ORAL | ANDA | 21 sections |
Quinine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53489-700 | CAPSULE | 324 mg | ORAL | NDA authorized generic | 32 sections |
Quinine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-811 | CAPSULE | 324 mg | ORAL | ANDA | 20 sections |
Quinine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-811 | CAPSULE | 324 mg | ORAL | ANDA | 20 sections |
Quinine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68084-947 | CAPSULE | 324 mg | ORAL | NDA authorized generic | 31 sections |
QUININE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-560 | CAPSULE | 324 mg | ORAL | ANDA | 20 sections |